Adaptive Biotechnologies Corporation (ADPT)
Symbol Info
Listed Symbol ADPT
Name Adaptive Biotechnologies Corporation
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $55,663,000
Latest Fiscal EPS $-0.44
Price Info
21 Day Moving Average $34.3010
21 Day EMA $33.575030
50 Day Moving Average $39.8288
50 Day EMA $36.591320
200 Day EMA $-
200 Day Moving Average -
52 Week High $55.12
52 Week Low $27.39
52 Week Change $
Alpha -0.050688
Beta -18.0318
Standard Deviation 0.300811
R2 0.927492
Periods 4
Share Information
10 Day Average Volume 581,680
20 Day Average Volume 658,164
30 Day Average Volume 605,136
50 Day Average Volume 522,056
Outstanding Shares 124,287,992
Float Shares 118,482,117
Percent Float 95.33%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 189
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 576,963
Institute Holdings Percent 67.300000
Institute Sold Previous 3 Months 109,383
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 16
Insider Holdings Percent 4.70%
Insider Sold Previous 3 Months -
Insiders Shares Owned 5,805,875
Price Change
7 Day Price Change $-4.0999985
7 Day Percent Change -12.96%
21 Day Price Change $-12.66
21 Day Percent Change -31.49%
30 Day Price Change $-14.219997
30 Day Percent Change -34.05%
Month To Date Price Change $-3.36
Month To Date Percent -10.87%
90 Day Price Change $-10.099998
90 Day Percent Change -26.83%
Quarter To Date $-3.359999
Quarter To Date Percent -10.87%
180 Day Price Change $-
180 Day Percent Change -
200 Day Price Change $-
200 Day Percent Change -
Year To Date $-
Year To Date Percent -
Profile
Description Adaptive Biotechnologies Corp is a a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Details
Issue Type CS
Market Cap $3,422,891,300
Sec Type
Auditor Ernst & Young LLP
Total Shares Outstanding 124,287,992
CEO Chad Robins
Employees 346
Last Audit UQ
Classification
CIK 0001478320
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1551 Eastlake Avenue East
Suite 200
Seattle, WA 98102
Website https://www.adaptivebiotech.com
Facisimile +1 206 659-0667
Telephone +1 206 659-0067
Email
Key Ratios
Profitability
EBIT Margin -85.9
EBITDA Margin -76.2
Pre-Tax Profit Margin -
Profit Margin Cont -80.38
Gross Margin 69.10
Profit Margin TOT -80.38
Income Statements
Revenue $69,184,000
Revenue Per Share $0.5566
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $3,417,497,952
Price To Sales 49.475190
Price To Free Cash 15.800000
PE High Last 5 Years -
Price To Book 16.6
Price To Cash Flow 15.0
PE Low Last 5 Years -
Price To Tangible Book -9
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 5.9
Leverage Ratio -6.1
Quick Ratio 5.7
Long Term Debt To Capital -
Assets
Receivables Turnover 10.8
Invoice Turnover 4.10
Assets Turnover 0.10
Management Effectiveness
Return Assets -9.39
Return On Equity 19.86
Return On Capital -910.11
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ADPT
Adaptive B..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.